Dongping Dai
FDA investigator
Appears on 1 document from 2019, mostly at sites in India. Most often cites sampling and testing of in-process materials and drug products (21 CFR 211.110(a)).
- 1
- Documents on file
- 8.0
- Observations per 483
- 2019
- First seen
- 2019
- Most recent
What they cite most
From 8 observations- 21 CFR 211.110(a)Sampling and testing of in-process materials and drug products2
- 21 CFR 211.100(a)Written procedures; deviations1
- 21 CFR 211.113(b)Control of microbiological contamination1
- 21 CFR 211.160(b)General requirements1
- 21 CFR 211.192Production record review1
- 21 CFR 211.22(d)Responsibilities of quality control unit1
Activity by year
2019: 1
Where
India 1
Often inspects with
Is Dongping Dai coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2019-12-13 | 483 Sun Pharmaceutical Industries Ltd.Dec 13, 2019 · Halol, India | Halol, India | 8 |
About this profile
What does Dongping Dai inspect?
Dongping Dai appears on 1 document on file covering 1 site, mostly in India.
What do they cite most often?
21 CFR 211.110(a) (sampling and testing of in-process materials and drug products), followed by 21 CFR 211.100(a) and 21 CFR 211.113(b).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Dongping Dai is dated Dec 13, 2019.